Stock listing
A2QG4Z Stock Price, News, Filings & Events — Opus Genetics, Inc.
Selected listing: A2QG4Z · LS · EUR · DE
This page tracks Opus Genetics, Inc.'s A2QG4Z:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2QG4Z:LS. A2QG4Z:LS is the stock-level entry point for investors researching Opus Genetics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A2QG4Z:LS
- Asset type
- Stock
- Market cap
- $502.5M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Opus Genetics, Inc. A2QG4Z:LS stock context
This page tracks Opus Genetics, Inc.'s A2QG4Z:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2QG4Z:LS. A2QG4Z:LS is the stock-level entry point for investors researching Opus Genetics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Opus Genetics, Inc.
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting wit...
September 9, 2026
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
August 6, 2026
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
August 3, 2026
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
July 9, 2026
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
July 6, 2026
Research Opus Genetics, Inc.
Opus Genetics, Inc. investor report
Review AI stock analysis and investor report context for A2QG4Z:LS.
Opus Genetics, Inc. company profile
View the public company page for Opus Genetics, Inc. on 6ix.
Opus Genetics, Inc. news
Read company news and market updates connected to Opus Genetics, Inc..
Opus Genetics, Inc. investor events
Find investor webinars, events, and replay context for Opus Genetics, Inc..
Alternate listings
IRD:NASDAQ
US · USD
Alternate listing for Opus Genetics, Inc.; the primary context on this page is A2QG4Z:LS.
R3X1:GETTEX
DE · EUR
Alternate listing for Opus Genetics, Inc.; the primary context on this page is A2QG4Z:LS.
A2QG4Z:LSX
DE · EUR
Alternate listing for Opus Genetics, Inc.; the primary context on this page is A2QG4Z:LS.
R3X1:FWB
DE · EUR
Alternate listing for Opus Genetics, Inc.; the primary context on this page is A2QG4Z:LS.
IRD:BOATS
US · USD
Alternate listing for Opus Genetics, Inc.; the primary context on this page is A2QG4Z:LS.
R3X1:TRADEGATE
DE · EUR
Alternate listing for Opus Genetics, Inc.; the primary context on this page is A2QG4Z:LS.
R3X1:DUS
DE · EUR
Alternate listing for Opus Genetics, Inc.; the primary context on this page is A2QG4Z:LS.
R3X1:MUN
DE · EUR
Alternate listing for Opus Genetics, Inc.; the primary context on this page is A2QG4Z:LS.
R3X1:SWB
DE · EUR
Alternate listing for Opus Genetics, Inc.; the primary context on this page is A2QG4Z:LS.